Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469530 · ClinicalTrials.gov registry record · Phase 2
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
A Phase 2 study of Solid Tumor, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 5
- Study locations
NCT04469530: Recruiting Phase 2 study of Solid Tumor, sponsored by Emory University.
NCT04469530 is a Phase 2 study of Solid Tumor that is actively recruiting participants, run by Emory University. The registered enrollment target is 55 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04469530, a Phase 2 study of Solid Tumor, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
Primary Outcome
Two-year progression-free survival in patients with high-risk solid tumors who complete a 12- month course of maintenance chemotherapy with daily sirolimus and twice daily celecoxib on a backbone of low-dose oral metronomic chemotherapy following completion of "standard" therapy as compared to a historical cohort of matched patients treated with observation only following completion of "standard" therapy.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Sirolimus
- DRUG Etoposide
- DRUG Celecoxib
Study Locations (5)
Georgia
- Aflac Cancer & Blood Disorders Centers - Atlanta
- Children's Healthcare of Atlanta - Atlanta
Missouri
- Washington University School of Medicine - St Louis
Pennsylvania
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Texas
- Texas Children's Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
What NCT04469530 shows while recruiting
NCT04469530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04469530 lists 5 locations in 4 states (Georgia, Missouri, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT04469530 about?
NCT04469530 is a clinical study titled "Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors". The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as...
What is the current status of trial NCT04469530?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2020-09-16. Estimated completion is 2029-02.
What conditions does trial NCT04469530 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04469530?
The interventions under investigation include: Cyclophosphamide (DRUG), Sirolimus (DRUG), Etoposide (DRUG), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT04469530?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04469530 being conducted?
This trial has 5 study locations across Georgia, Missouri, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04469530's enrollment target sits among peer trials
55 115th of 196 higher than 81 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI